Medicine

Comment on "Efficacy and safety of atezolizumab and bevacizumab with or without TACE as first-line therapy for unresectable HCC: a multicenter cohort study".

Huikang Wang, Xinjun Xu, Xicheng Song, Yu Zhang

2026.1.3Hepatology International

DOI: 10.1007/s12072-025-10970-9

Abstract

Abstract is not available.

Citation format

WANG, Huikang, et al. Comment on "efficacy and safety of atezolizumab and bevacizumab with or without TACE as first-line therapy for unresectable HCC: A multicenter cohort study". Hepatology International, 2026.